Details of Drug-Drug Interaction
| Drug General Information (ID: DDIT6I1OUK) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Amantadine | Drug Info | Bupropion | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antiviral Agents | Antidepressants | |||||||
| Structure | |||||||||
| Mechanism of Amantadine-Bupropion Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of lowers seizure threshold Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Amantadine | Bupropion | |||||||
| Mechanism | Lower seizure threshold | Lower seizure threshold | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Lowers seizure threshold | ||||||||
| Factor Description | The combination of medications that lower the seizure threshold is a factor that makes people with epilepsy more likely to have seizures. A seizure is a sudden, uncontrolled electrical disturbance in the brain that can cause changes in your behavior, movements or sensations, and level of consciousness. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Extreme caution is advised if bupropion is administered with amantadine, particularly in the elderly and in patients with a history of seizures or other risk factors for seizures (e.g., head trauma brain tumor severe hepatic cirrhosis metabolic disorders CNS infections excessive use of alcohol or sedatives addiction to opiates, cocaine, or stimulants diabetes treated with oral hypoglycemic agents or insulin). The manufacturer recommends a lower initial dosage of bupropion and gradual dosage increments in patients receiving the drugs concurrently. The total dose of bupropion should generally not exceed 450 mg/day (or 150 mg every other day in patients with severe hepatic cirrhosis). Bupropion should be discontinued and not restarted in patients who experience a seizure during treatment. | ||||||||